The continual innovation of commercial PET/CT solutions in nuclear cardiology: Siemens Healthineers.

Cardiac PET/CT is an evolving, non-invasive imaging modality that impacts patient management in many clinical scenarios. Beyond offering the capability to assess myocardial perfusion, inflammatory cardiac pathologies, and myocardial viability, cardiac PET/CT also allows for the non-invasive quantitative assessment of myocardial blood flow (MBF) and myocardial flow reserve (MFR). Recognizing the need for an enhanced comprehension of coronary physiology, Siemens Healthineers implemented a sophisticated solution for the calculation of MBF and MFR in 2009. As a result, each aspect of their innovative scanner and image-processing technology seamlessly integrates into an efficient, easy-to-use workflow for everyday clinical use that maximizes the number of patients who potentially benefit from this imaging modality.

Quantitative imaging test approval and biomarker qualification: interrelated but distinct activities.

UNLABELLED: Quantitative imaging biomarkers could speed the development of new treatments for unmet medical needs and improve routine clinical care. However, it is not clear how the various regulatory and nonregulatory (eg, reimbursement) processes (often referred to as pathways) relate, nor is it clear which data need to be collected to support these different pathways most efficiently, given the time- and cost-intensive nature of doing so. The purpose of this article is to describe current thinking regarding these pathways emerging from diverse stakeholders interested and active in the definition, validation, and qualification of quantitative imaging biomarkers and to propose processes to facilitate the development and use of quantitative imaging biomarkers. A flexible framework is described that may be adapted for each imaging application, providing mechanisms that can be used to develop, assess, and evaluate relevant biomarkers. From this framework, processes can be mapped that would be applicable to both imaging product development and to quantitative imaging biomarker development aimed at increasing the effectiveness and availability of quantitative imaging. SUPPLEMENTAL MATERIAL: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.10100800/-/DC1.

From a PMT-based to a SiPM-based PET system: a study to define matched acquisition/reconstruction parameters and NEMA performance of the Biograph Vision 450.

BACKGROUND: The purpose of this work was to propose an approach based on noise measurement to adapt present clinical acquisition and reconstruction parameters adapted to a PMT-based system (Biograph mCT) to a SiPM-based system (Biograph Vision 450) sharing identical geometrical properties. The NEMA performance (NEMA) of the recently released Biograph Vision 450 PET/CT (Vision) was also derived. METHODS: All measurements were conducted on Vision and Biograph mCT with TrueV (mCT). A full NEMA-based performance was derived for Vision only. The adaptation of acquisition and reconstruction parameters from mCT to Vision was done using the NEMA image quality phantom. The noise level reached using mCT was set as the reference value for six different numbers of net true coincidences. The noise level computed using Vision was matched to the reference noise level (within 0.01%) using a different reconstruction set-up to determine the potential reduction of count numbers for the same noise level. RESULTS: Vision sensitivity was 9.1 kcps/MBq for a timing resolution of 213 ps at 5.3 kBq/mL. The NEMA-based CR for the 10-mm sphere was better than 75% regardless the reconstruction set-up studied. The mCT reference noise properties could be achieved using Vision with a scan time reduction (STR) of 1.34 with four iterations and a 440 × 440 matrix size (or STR = 1.89 with a 220 × 220 matrix size) together with a 3D CR improvement of 53% for the 10-mm sphere (24% using 220 × 220). CONCLUSION: The Vision exhibited improved NEMA performances compared to mCT. Using the proposed approach, the time acquisition could be divided by almost two, while keeping the same noise properties as that of mCT with a marked improvement of contrast recovery.

Method for transforming CT images for attenuation correction in PET/CT imaging.

A tube-voltage-dependent scheme is presented for transforming Hounsfield units (HU) measured by different computed tomography (CT) scanners at different x-ray tube voltages (kVp) to 511 keV linear attenuation values for attenuation correction in positron emission tomography (PET) data reconstruction. A Gammex 467 electron density CT phantom was imaged using a Siemens Sensation 16-slice CT, a Siemens Emotion 6-slice CT, a GE Lightspeed 16-slice CT, a Hitachi CXR 4-slice CT, and a Toshiba Aquilion 16-slice CT at kVp ranging from 80 to 140 kVp. All of these CT scanners are also available in combination with a PET scanner as a PET/CT tomograph. HU obtained for various reference tissue substitutes in the phantom were compared with the known linear attenuation values at 511 keV. The transformation, appropriate for lung, soft tissue, and bone, yields the function 9.6 x 10(-5). (HU+ 1000) below a threshold of approximately 50 HU and a (HU+ 1000)+b above the threshold, where a and b are fixed parameters that depend on the kVp setting. The use of the kVp-dependent scaling procedure leads to a significant improvement in reconstructed PET activity levels in phantom measurements, resolving errors of almost 40% otherwise seen for the case of dense bone phantoms at 80 kVp. Results are also presented for patient studies involving multiple CT scans at different kVp settings, which should all lead to the same 511 keV linear attenuation values. A linear fit to values obtained from 140 kVp CT images using the kVp-dependent scaling plotted as a function of the corresponding values obtained from 80 kVp CT images yielded y = 1.003 x -0.001 with an R2 value of 0.999, indicating that the same values are obtained to a high degree of accuracy.

Optimizing injected dose in clinical PET by accurately modeling the counting-rate response functions specific to individual patient scans.

UNLABELLED: To optimize the injected dose of radiopharmaceutical in PET, one needs to know its relationship to some metric of data quality for individual patient scans, such as noise-equivalent counting rate (NECR). In this paper, we show how one may accurately model the clinical NECR response corresponding to specific patient scans much as if a counting-rate test had been performed on each patient. We apply this technique to patient data and show how it can lead to improved clinical scanning protocols. METHODS: True and random coincidence rates expressed as functions of an appropriate measurable system parameter such as the detector single-event rate have functional forms that are largely independent of the object being scanned. Thus, reference true and random response functions may be scaled directly to the specific counting rates measured on a clinical scan, thereby yielding a curve of NECR versus injected dose. We have applied this technique to 2 groups of 163 clinical (18)F-FDG scans each. One of the groups was obtained on a lutetium oxyorthosilicate PET/CT scanner with conventional front-end electronics, and the other was obtained on a lutetium oxyorthosilicate PET/CT scanner with a new digital data processing system (Pico-3D). RESULTS: At 90%-95% of maximum signal-to-noise ratio (SNR), the mean optimal dose for a 60-min uptake period ranged from 366 to 717 MBq depending on the electronics and randoms processing method. There was only a slight (1 MBq/kg) dependence of optimal dose on patient weight but a larger dependence on position in the body. Pico-3D electronics improved optimal data SNR by 35% for a 70-kg person, but in both cases NECR fell rapidly with increasing weight (1.4%/kg). For an equivalent data SNR, a 120-kg person would have to be scanned 2.3 times longer than a 60-kg person. Over this range of weight, the mean scatter fraction increased by 12% whereas the ratio of mean randoms to trues increased by 48%. CONCLUSION: The methodology developed here allows one to directly estimate the optimal dose to inject for specific clinical scans and permits a detailed analysis of the sources of noise in PET data and of their variation with parameters such as patient weight.

First experimental results of time-of-flight reconstruction on an LSO PET scanner.

Time-of-flight (TOF) positron emission tomography (PET) was studied and preliminarily developed in the 1980s, but the lack of a scintillator able to deliver at the same time proper time resolution and stopping power has prevented this technique from becoming widespread and commercially available. With the introduction of LSO in PET, TOF is now a feasible option. TOF reconstruction has been implemented in the CPS Hi-Rez PET scanner, both with 2D filtered-back-projection (FBP2D) and 3D ordered subset expectation maximization (OSEM3D). A new procedure has been introduced in the time alignment to compensate for the limited digital time resolution of the present electronics. A preliminary version of scatter correction for TOF has been devised and is presented. The measured time resolution of 1.2 ns (FWHM) allowed for a signal-to-noise ratio increase of about 50% in phantoms of about 40 cm transaxial size, or a gain larger than 2 in noise equivalent counts (NEC). TOF reconstruction has shown the expected improvement in SNR, both in simulation and experimental data. First experimental results show two improvements of TOF reconstruction over conventional (non-TOF) reconstruction: a lower noise level and a better capability to resolve structures deep inside large objects.

NEMA NU 2 performance tests for scanners with intrinsic radioactivity.

Performance tests on lutetium oxyorthosilicate (LSO)-based PET scanners cannot be conducted strictly according to the National Electrical Manufacturers Association (NEMA) NU 2 standards because of the presence of intrinsic radioactivity within the LSO crystal scintillator material. This background radiation gives rise mainly to random coincidence events but also to a small number of true coincidences, which cannot be eliminated from measurements on such scanners and must therefore be corrected for in the data analysis. The current NU 2 standards do not take account of these backgrounds and hence can lead to erroneous results on LSO-based machines. Nevertheless, the intent of the standards can be met with appropriate modifications to the acquisition and processing procedures. In this paper, we propose certain changes to the NEMA specifications to accommodate this class of scanners. These changes affect mainly the estimation of sensitivity, scatter, randoms, and count losses. Using these modified procedures, the NU 2 performance of LSO-based systems can accurately be measured.

Optimization of injected dose based on noise equivalent count rates for 2- and 3-dimensional whole-body PET.

UNLABELLED: The noise equivalent count (NEC) rate index is used to derive guidelines on the optimal injected dose to the patient for 2-dimensional (2D) and 3-dimensional (3D) whole-body PET acquisitions. METHODS: We performed 2D and 3D whole-body acquisitions of an anthropomorphic phantom modeling the conditions for (18)F-FDG PET of the torso and measured the NEC rates for different activity levels for several organs of interest. The correlations between count rates measured from the phantom and those from a series of whole-body patient scans were then analyzed. This analysis allowed validation of our approach and estimation of the injected dose that maximizes NEC rate as a function of patient morphology for both acquisition modes. RESULTS: Variations of the phantom and patient prompt and random coincidence rates as a function of single-photon rates correlated well. On the basis of these correlations, we demonstrated that the patient NEC rate can be predicted for a given single-photon rate. Finally, we determined that patient single-photon rates correlated with the mean dose per weight at acquisition start when normalized by the body mass index. This correlation allows modifying the injected dose as a function of patient body mass index to reach the peak NEC rate in 3D mode. Conversely, we found that the peak NEC rates were never reached in 2D mode within an acceptable range of injected dose. CONCLUSION: The injected dose was adapted to patient morphology for 2D and 3D whole-body acquisitions using the NEC rate as a figure of merit of the statistical quality of the sinogram data. This study is a first step toward a more comprehensive comparison of the image quality obtained using both acquisition modes.